spacer
home > ebr > spring 2019 > bridging the gap
PUBLICATIONS
European Biopharmaceutical Review

Bridging the Gap

Regenerative medicine (the art of repairing or replacing damaged tissues and organs through cellular engineering) has seen remarkable advances in the past decade. Positive clinical trial results, particularly in cancer immunotherapy, have prompted a surge in the number of cell-based therapies progressing toward commercialisation. Apheresis and cell collection centres must quickly adapt to handle the increased demand for cell therapy starting materials. Concerns over upholding quality oversight, particularly for Good Manufacturing Practice (GMP)-qualified starting materials, should also be addressed.

Apheresis collection centres interact closely with both donors and the pharmaceutical companies developing cellular therapies and are, therefore, in an ideal position to devise solutions to these challenges. This article will focus on how apheresis facilities aim to adapt collection centre infrastructure to support higher demand while streamlining downstream processing and ensuring quality oversight. The authors will examine specific quality control challenges posed by cryopreserved GMP products and the related need to adapt and standardise cold chain protocols. Bridging the gap from donor collection to successful therapeutic relies on the ability to collect high-quality starting material and assure that the finest quality and efficacy of the final cell-based product can be achieved.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dominic Clarke PhD has over 15 years’ experience developing enabling solutions for cell therapy and bioprocessing applications. Dominic is the Global Head of Cell Therapy at HemaCare, where he is actively engaged with industry experts to ensure the highest quality materials are delivered. Previously, he held roles as the Global Product Manager for Charter Medical’s cell therapy and bioprocessing disposables portfolio, focussed on creating flexible closed-system solutions for early- and late-stage production, and as the Director of Research and Development at BioLife Solutions, developing novel biopreservation media and methods to support extended stability of cells and tissues.

Brad N Taylor PhD is the Senior Product Manager at HemaCare. Brad has over 13 years’ experience in the biotechnology industry, addressing multiple aspects of drug discovery and preclinical development. Previously, he held roles as Application Scientist and Product Manager in the in vivo imaging division of PerkinElmer, where he worked to bring innovative solutions to market to assist the research community in expediting and streamlining the process of preclinical drug discovery for cancer and other clinical applications in animal models of disease.
spacer
Dominic Clarke PhD
spacer
spacer
spacer
Brad N Taylor PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Microalgae Culture Using the DASGIP® PBR4 Module for Illumination with a New Brunswick™ CelliGen® 310 Stirred-tank Bioreactor

Eppendorf

The number of bioprocess applications for microalgae has increased in recent years, particularly in the fi eld of biofuel production. The combination of the New Brunswick CelliGen 310 stirred-tank bioreactor and the DASGIP LED Illumination System creates a bioreactor setup which is capable of supporting high density microalgal growth. Using the stand-alone Eppendorf DASGIP PBR4 Module, LED illumination spectra and intensities can be controlled for optimal support of all types of chlorophylls and carotenoids. For this study in which high density culture of up to 1.5 x 107 cells/mL was achieved, the unicellular freshwater alga, Dunaliella tertiolecta, was used.
More info >>

 
Industry Events

BioPharm America™ 2019—12th Annual International Partnering Conference

11-12 September 2019, Boston Convention and Exhibition Center (BCEC), Boston, MA 02210 USA

BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development. Life science executives from around the world gather to identify, meet and to enter into strategic relationships facilitated by partneringONE®, the world’s leading web-based partnering system. BioPharm America is the only event in North America based on the same reputable formula as EBD Group’s acclaimed European events BIO-Europe® and BIO-Europe Spring®. BioPharm America annually attracts 800+ delegates from over 500 companies who participated in 2,300+ scheduled one-to-one meetings. BioPharm America is now part of Biotech Week Boston, and together they draw a total of over 4,500 life science leaders, scientists and innovators.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement